LLY

1,075.36

-2.69%↓

JNJ

206.6

-0.54%↓

ABBV

227.76

+0.1%↑

UNH

330.04

+0.11%↑

AZN

92.73

-0.69%↓

LLY

1,075.36

-2.69%↓

JNJ

206.6

-0.54%↓

ABBV

227.76

+0.1%↑

UNH

330.04

+0.11%↑

AZN

92.73

-0.69%↓

LLY

1,075.36

-2.69%↓

JNJ

206.6

-0.54%↓

ABBV

227.76

+0.1%↑

UNH

330.04

+0.11%↑

AZN

92.73

-0.69%↓

LLY

1,075.36

-2.69%↓

JNJ

206.6

-0.54%↓

ABBV

227.76

+0.1%↑

UNH

330.04

+0.11%↑

AZN

92.73

-0.69%↓

LLY

1,075.36

-2.69%↓

JNJ

206.6

-0.54%↓

ABBV

227.76

+0.1%↑

UNH

330.04

+0.11%↑

AZN

92.73

-0.69%↓

Kodu・Aktsiate loetelu・Ventyx Biosciences Inc

Ventyx Biosciences Inc

Suletud

9.97 -0.3

Osta Müü

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

9.85

Max

10.13

Põhinäitajad
By Trading Economics
Sissetulek	4.2M -23M
Kasumimarginaal	-2,027.003
Töötajad	83
EBITDA	6.6M -23M

Soovitused
By TipRanks
Soovitused	Tugev "osta" hinnang
12 kuu keskmine prognoos	+36.84% upside

Turustatistika
By TradingEconomics
Turukapital	123M 710M
Eelmine avamishind	10.27
Eelmine sulgemishind	9.97

Ventyx Biosciences Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

28. nov 2025, 15:29 UTC

Suurimad hinnamuutused turgudel

Omandamised, ülevõtmised, äriostud

China's Jiangxi Copper Rejected by SolGold in $1 Billion Takeover Approach

28. nov 2025, 21:50 UTC

Market Talk

Auto & Transport Roundup: Market Talk

28. nov 2025, 19:59 UTC

Market Talk

Oil Futures Settle Lower in Slow Black Friday Trade -- Market Talk

28. nov 2025, 19:47 UTC

Market Talk

U.S. Natural Gas Lifted By Cold Weather Outlook -- Market Talk

28. nov 2025, 18:16 UTC

Market Talk

Global Equities Roundup: Market Talk

28. nov 2025, 18:16 UTC

Market Talk

Messy Canada GDP Data Still Seen as Cause for Optimism in 2026 -- Market Talk

28. nov 2025, 18:08 UTC

Market Talk

Market Talk Roundup: Latest on U.S. Politics

28. nov 2025, 18:08 UTC

Market Talk

Messy Canada GDP Data Still Seen as Cause for Optimism in 2026 -- Market Talk

28. nov 2025, 17:48 UTC

Market Talk

Bank of Canada May Revise Up Inflation Projections After GDP Data -- Market Talk

28. nov 2025, 17:20 UTC

Market Talk

Auto & Transport Roundup: Market Talk

28. nov 2025, 16:50 UTC

Omandamised, ülevõtmised, äriostud

Week's Best: Sieg's Stature at Citi Grows -- Barrons.com

28. nov 2025, 15:51 UTC

Market Talk

Canada Household Spending Edges Lower -- Market Talk

28. nov 2025, 15:33 UTC

Market Talk

Crude Futures Gain as U.S. Market Reopens -- Market Talk

28. nov 2025, 15:21 UTC

Market Talk

Gold Rises on U.S. Rate-Cut Bets After CME Outage -- Market Talk

28. nov 2025, 15:13 UTC

Market Talk

Dollar Recovers Slightly as Investors Already Price in Fed Rate Cut -- Market Talk

28. nov 2025, 15:11 UTC

Market Talk

Global Equities Roundup: Market Talk

28. nov 2025, 15:11 UTC

Market Talk

Canadian National Railway Showing Positive Trend Going Into 2026 -- Market Talk

28. nov 2025, 14:51 UTC

Market Talk

Canada GDP Report Masks Fragile State of Economy -- Market Talk

28. nov 2025, 14:41 UTC

Market Talk

Canada's GDP Level Pulled Higher by 'Eye-Opening' Revisions -- Market Talk

28. nov 2025, 14:37 UTC

Market Talk

U.S. Natural Gas Futures Rise As Temperatures Drop -- Market Talk

28. nov 2025, 14:33 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

28. nov 2025, 14:33 UTC

Market Talk

Steep Import Drop Fuels Surprise Lift in Canada GDP -- Market Talk

28. nov 2025, 14:20 UTC

Market Talk

Too Much Noise in Canada's Surprise 3Q GDP Gain -- Market Talk

28. nov 2025, 14:10 UTC

Market Talk

Canadian Nowcast Came Closest to Predicting Surprise 3Q Strength -- Market Talk

28. nov 2025, 13:39 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

28. nov 2025, 13:39 UTC

Market Talk

Canada Trade Data Could Face Larger-Than-Normal Revisions -- Market Talk

28. nov 2025, 13:36 UTC

Market Talk

Canada's Economy Expands More Than Expected -- Market Talk

28. nov 2025, 13:29 UTC

Market Talk

CME Outage Sowing Chaos Across Markets, Trade Nations Says -- Market Talk

28. nov 2025, 13:27 UTC

Market Talk

Russia-Ukraine Peace Efforts to Have Little Impact on Oil Fundamentals -- Market Talk

28. nov 2025, 13:19 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

Võrdlus sarnastega

Hinnamuutus

Ventyx Biosciences Inc Prognoos

Hinnasiht

By TipRanks

36.84% tõus

12 kuu keskmine prognoos

Keskmine 13.67 USD 36.84%

Kõrge 21 USD

Madal 2 USD

Põhineb 7 Wall Streeti analüütiku instrumendi Ventyx Biosciences Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Tugev "osta" hinnang

7 ratings

Osta

Hoia

Müü

Põhineb 7 analüütiku instrumendi Ventyx Biosciences Inc aktsia reitingul - viimase 3 kuu andmed.

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

Ettevõttest Ventyx Biosciences Inc

Ventyx Biosciences, Inc., a clinical-stage biopharmaceutical company, develops small molecule product candidates to address a range of inflammatory diseases. The company's lead clinical product candidate is VTX958, a selective allosteric tyrosine kinase type 2 inhibitor for psoriasis, psoriatic arthritis, and Crohn's disease. It is also developing VTX002, a sphingosine 1 phosphate receptor modulator that is in Phase II clinical trials for the treatment of ulcerative colitis; and VTX2735, a peripheral-targeted NOD-like receptor protein 3 inflammasome inhibitor to treat patients with cryopyrin-associated periodic syndrome. In addition, the company develops VTX3232, a CNS-penetrant NLRP3 inhibitor. Ventyx Biosciences, Inc. was incorporated in 2018 and is based in San Diego, California.